Literature DB >> 25754473

Cell-specific RNA aptamer against human CCR5 specifically targets HIV-1 susceptible cells and inhibits HIV-1 infectivity.

Jiehua Zhou1, Sangeetha Satheesan2, Haitang Li1, Marc S Weinberg3, Kevin V Morris4, John C Burnett1, John J Rossi5.   

Abstract

The C-C chemokine receptor type 5 (CCR5) is a receptor expressed by T cells and macrophages that serves as a coreceptor for macrophage-tropic HIV-1. Loss of CCR5 is associated with resistance to HIV-1. Here, we combine the live-cell-based SELEX with high-throughput sequencing technology to generate CCR5 RNA aptamers capable of specifically targeting HIV-1 susceptible cells (as small interfering RNA [siRNA] delivery agent) and inhibiting HIV-1 infectivity (as antiviral agent) via block of the CCR5 required for HIV-1 to enter cells. One of the best candidates, G-3, efficiently bound and was internalized into human CCR5-expressing cells. The G-3 specifically neutralized R5 virus infection in primary peripheral blood mononuclear cells, and in vivo generated human CD4(+) T cells with a nanomolar inhibitory concentration 50%. G-3 was also capable of transferring functional siRNAs to CCR5-expressing cells. Collectively, the cell-specific, internalizing, CCR5-targeted aptamers and aptamer-siRNA conjugates offer promise for overcoming some of the current challenges of drug resistance in HIV-1 by providing cell-type- or tissue-specific delivery of various therapeutic moieties.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25754473      PMCID: PMC4369413          DOI: 10.1016/j.chembiol.2015.01.005

Source DB:  PubMed          Journal:  Chem Biol        ISSN: 1074-5521


  44 in total

1.  Systemic administration of combinatorial dsiRNAs via nanoparticles efficiently suppresses HIV-1 infection in humanized mice.

Authors:  Jiehua Zhou; C Preston Neff; Xiaoxuan Liu; Jane Zhang; Haitang Li; David D Smith; Piotr Swiderski; Tawfik Aboellail; Yuanyu Huang; Quan Du; Zicai Liang; Ling Peng; Ramesh Akkina; John J Rossi
Journal:  Mol Ther       Date:  2011-09-27       Impact factor: 11.454

2.  Indicator cell lines for detection of primary strains of human and simian immunodeficiency viruses.

Authors:  M A Vodicka; W C Goh; L I Wu; M E Rogel; S R Bartz; V L Schweickart; C J Raport; M Emerman
Journal:  Virology       Date:  1997-06-23       Impact factor: 3.616

3.  Using aptamers evolved from cell-SELEX to engineer a molecular delivery platform.

Authors:  Prabodhika Mallikaratchy; Haipeng Liu; Yu Fen Huang; Hui Wang; Dalia Lopez-Colon; Weihong Tan
Journal:  Chem Commun (Camb)       Date:  2009-04-09       Impact factor: 6.222

Review 4.  Cell-specific aptamers for targeted therapies.

Authors:  Laura Cerchia; Paloma H Giangrande; James O McNamara; Vittorio de Franciscis
Journal:  Methods Mol Biol       Date:  2009

5.  Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras.

Authors:  Lee Adam Wheeler; Radiana Trifonova; Vladimir Vrbanac; Emre Basar; Shannon McKernan; Zhan Xu; Edward Seung; Maud Deruaz; Tim Dudek; Jon Ivar Einarsson; Linda Yang; Todd M Allen; Andrew D Luster; Andrew M Tager; Derek M Dykxhoorn; Judy Lieberman
Journal:  J Clin Invest       Date:  2011-05-16       Impact factor: 14.808

Review 6.  Therapeutic RNA aptamers in clinical trials.

Authors:  Padma Sundaram; Helena Kurniawan; Mark E Byrne; Jacek Wower
Journal:  Eur J Pharm Sci       Date:  2012-11-07       Impact factor: 4.384

Review 7.  Nucleic acid aptamers in human viral disease.

Authors:  Zhiren Zhang; Michael Blank; Hermann J Schluesener
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2004 Sep-Oct       Impact factor: 4.291

8.  Characterization of RANTES- and aminooxypentane-RANTES-triggered desensitization signals reveals differences in recruitment of the G protein-coupled receptor complex.

Authors:  A J Vila-Coro; M Mellado; A Martín de Ana; C Martínez-A; J M Rodríguez-Frade
Journal:  J Immunol       Date:  1999-09-15       Impact factor: 5.422

9.  An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4(+) T cell decline in humanized mice.

Authors:  Charles Preston Neff; Jiehua Zhou; Leila Remling; Jes Kuruvilla; Jane Zhang; Haitang Li; David D Smith; Piotr Swiderski; John J Rossi; Ramesh Akkina
Journal:  Sci Transl Med       Date:  2011-01-19       Impact factor: 17.956

10.  Endocytosis and recycling of the HIV coreceptor CCR5.

Authors:  N Signoret; A Pelchen-Matthews; M Mack; A E Proudfoot; M Marsh
Journal:  J Cell Biol       Date:  2000-12-11       Impact factor: 10.539

View more
  34 in total

Review 1.  Aptamers in HIV research diagnosis and therapy.

Authors:  Jyoti Bala; Srinivasan Chinnapaiyan; Rajib Kumar Dutta; Hoshang Unwalla
Journal:  RNA Biol       Date:  2018-02-12       Impact factor: 4.652

Review 2.  Recent advances in RNAi-based strategies for therapy and prevention of HIV-1/AIDS.

Authors:  Manjunath N Swamy; Haoquan Wu; Premlata Shankar
Journal:  Adv Drug Deliv Rev       Date:  2016-03-21       Impact factor: 15.470

Review 3.  Manipulating the in vivo immune response by targeted gene knockdown.

Authors:  Judy Lieberman
Journal:  Curr Opin Immunol       Date:  2015-07-03       Impact factor: 7.486

Review 4.  Current Progress in Non-viral RNAi-Based Delivery Strategies to Lymphocytes.

Authors:  Shoshy Mizrahy; Inbal Hazan-Halevy; Niels Dammes; Dalit Landesman-Milo; Dan Peer
Journal:  Mol Ther       Date:  2017-04-06       Impact factor: 11.454

5.  Dimerization of an aptamer generated from Ligand-guided selection (LIGS) yields a high affinity scaffold against B-cells.

Authors:  Sana Batool; Kimon V Argyropoulos; Roksana Azad; Precious Okeoma; Hasan Zumrut; Sanam Bhandari; Rigzin Dekhang; Prabodhika R Mallikaratchy
Journal:  Biochim Biophys Acta Gen Subj       Date:  2018-10-17       Impact factor: 3.770

Review 6.  Nanotechnology Approaches for the Delivery of Exogenous siRNA for HIV Therapy.

Authors:  Simeon K Adesina; Emmanuel O Akala
Journal:  Mol Pharm       Date:  2015-11-09       Impact factor: 4.939

7.  Improvements and Limitations of Humanized Mouse Models for HIV Research: NIH/NIAID "Meet the Experts" 2015 Workshop Summary.

Authors:  Ramesh Akkina; Atef Allam; Alejandro B Balazs; Joel N Blankson; John C Burnett; Sofia Casares; J Victor Garcia; Kim J Hasenkrug; Fatah Kashanchi; Scott G Kitchen; Florian Klein; Priti Kumar; Andrew D Luster; Larisa Y Poluektova; Mangala Rao; Brigitte E Sanders-Beer; Leonard D Shultz; Jerome A Zack
Journal:  AIDS Res Hum Retroviruses       Date:  2016-02       Impact factor: 2.205

8.  Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies.

Authors:  Xin Xia; Haitang Li; Sangeetha Satheesan; Jiehua Zhou; John J Rossi
Journal:  J Vis Exp       Date:  2019-01-07       Impact factor: 1.355

9.  HIV Replication and Latency in a Humanized NSG Mouse Model during Suppressive Oral Combinational Antiretroviral Therapy.

Authors:  Sangeetha Satheesan; Haitang Li; John C Burnett; Mayumi Takahashi; Shasha Li; Shiny Xiaqin Wu; Timothy W Synold; John J Rossi; Jiehua Zhou
Journal:  J Virol       Date:  2018-03-14       Impact factor: 5.103

Review 10.  Aptamers as Modular Components of Therapeutic Nucleic Acid Nanotechnology.

Authors:  Martin Panigaj; M Brittany Johnson; Weina Ke; Jessica McMillan; Ekaterina A Goncharova; Morgan Chandler; Kirill A Afonin
Journal:  ACS Nano       Date:  2019-11-05       Impact factor: 15.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.